✦ LIBER ✦

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan

✍ Scribed by Gabrielle Gossner; Robert L. Coleman; David G. Mutch; Neil S. Horowitz; Janet S. Rader; Randall K. Gibb; Matthew A. Powell; Thomas J. Herzog

Book ID: 113960538
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 270 KB
Volume: 103
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2006.02.026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of bevacizumab and pegylated lip

Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers

✍ Kazuya Kudoh; Masashi Takano; Hiroko Kouta; Ryoko Kikuchi; Tsunekazu Kita; Morik 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 402 KB

Pegylated liposomal doxorubicin as a sin

Pegylated liposomal doxorubicin as a single agent or as combination therapy with carboplatin in patients with recurrent or refractory epithelial ovarian cancer

✍ Keng Shen; Beihua Kong; Yunong Gao; Lingying Wu; Ziting Li; Yile Chen; Mengda Li 📂 Article 📅 2009 🏛 Springer-Verlag ⚖ 360 KB

AMG 386 combined with either pegylated l

AMG 386 combined with either pegylated liposomal doxorubicin or topotecan in patients with advanced ovarian cancer: Results from a phase Ib study

✍ R. Wenham; R. Schilder; C. Pippitt; S. Wong; S. Ananda; S. Scudder; R. Melara; N 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB

A phase II clinical trial of pegylated l

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

✍ Marcela G. del Carmen; John Micha; Laurie Small; Daron G. Street; Anil Londhe; T 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 254 KB

Phase II evaluation of topotecan and nav

Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer

✍ Thomas J. Herzog; Matthew A. Powell; Janet S. Rader; Randall K. Gibb; Lynne Lipp 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 424 KB

Phase II evaluation of a 3-day infusion

Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer

✍ Thomas J. Herzog; Matthew A. Powell; Janet S. Rader; Randall Gibb; David G. Mutc 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 127 KB